Seattle Children’s Set to Launch First U.S. CAR T-Cell Clinical Trial for Children with Lupus

May is National Lupus Awareness Month and we’re celebrating the fact that Seattle Children’s has received FDA authorization to launch the first chimeric antigen receptor (CAR) T-cell clinical trial in the U.S. for children under 18 with the most common form of lupus.

Systemic lupus erythematosus is a chronic autoimmune disorder that affects multiple organ systems, resulting in significant morbidity and mortality. Approximately 20% of lupus patients have disease onset during childhood, and children with lupus are at particular risk for severe disease and worse long-term outcomes.

You can read more about this first-ever U.S. trial at the Seattle Children’s On the Pulse blog.

We want to thank our amazing community of Children’s Miracle Network Hospitals fundraising partners. Your giving ensures that Seattle Children’s is at the forefront of pediatric medical research, working to cure childhood disease and improve outcomes for children all over the world.